Danaher to Acquire Masimo in $9.9B Deal to Boost Diagnostics Portfolio

Danaher Corp. has signed a definitive agreement to acquire all outstanding shares of Irvine, Calif.-based Masimo Corp. for $180 per share in cash, valuing the company at approximately $9.9 billion in total enterprise value.

Masimo is known for its pulse oximetry and advanced patient-monitoring technologies widely used in acute care environments. Danaher said the acquisition will enhance its diagnostics segment and create new opportunities to expand Masimo’s global footprint.

“Masimo’s advanced sensor technology and AI-enabled monitoring bring powerful new capabilities to our diagnostics portfolio,” said Julie Sawyer Montgomery, executive vice president for diagnostics at Danaher. “Integrating these strengths into Danaher will create meaningful opportunities to innovate for clinicians and improve decision-making in critical settings.”

Following the close of the transaction, Masimo will operate as a standalone company within Danaher’s diagnostics segment.

The deal is expected to close in the second half of 2026, pending regulatory approvals and approval by Masimo shareholders.